Liposome imaging agents in personalized medicine

Adv Drug Deliv Rev. 2012 Oct;64(13):1417-35. doi: 10.1016/j.addr.2012.09.003. Epub 2012 Sep 12.


In recent years the importance of molecular and diagnostic imaging has increased dramatically in the treatment planning of many diseases and in particular in cancer therapy. Within nanomedicine there are particularly interesting possibilities for combining imaging and therapy. Engineered liposomes that selectively localize in tumor tissue can transport both drugs and imaging agents, which allows for a theranostic approach with great potential in personalized medicine. Radiolabeling of liposomes have for many years been used in preclinical studies for evaluating liposome in vivo performance and has been an important tool in the development of liposomal drugs. However, advanced imaging systems now provide new possibilities for non-invasive monitoring of liposome biodistribution in humans. Thus, advances in imaging and developments in liposome radiolabeling techniques allow us to enter a new arena where we start to consider how to use imaging for patient selection and treatment monitoring in connection to nanocarrier based medicines. Nanocarrier imaging agents could furthermore have interesting properties for disease diagnostics and staging. Here, we review the major advances in the development of radiolabeled liposomes for imaging as a tool in personalized medicine.

Publication types

  • Review

MeSH terms

  • Animals
  • Diagnostic Imaging / methods*
  • Humans
  • Liposomes
  • Neoplasms / diagnosis
  • Precision Medicine*
  • Radiopharmaceuticals / administration & dosage*


  • Liposomes
  • Radiopharmaceuticals